|
|
Volumn 13, Issue 2, 2014, Pages 85-89
|
|
2013 FDA drug approvals
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
AFATINIB;
ALOGLIPTIN;
BAZEDOXIFENE PLUS CONJUGATED ESTROGEN;
CANAGLIFLOZIN;
CRIZOTINIB;
DABRAFENIB;
DOLUTEGRAVIR;
ESLICARBAZEPINE ACETATE;
FLUTEMETAMOL F 18;
FLUTICASONE FUROATE PLUS VILANTEROL;
FUMARIC ACID DIMETHYL ESTER;
GADOTERATE MEGLUMINE;
IBRUTINIB;
LULICONAZOLE;
MACITENTAN;
MIPOMERSEN;
OBINUTUZUMAB;
OLYSIO;
OSPEMIFENE;
POMALIDOMIDE;
RADIUM CHLORIDE RA 223;
RIOCIGUAT;
SIMEPREVIR;
SOFOSBUVIR;
SOVALDI;
TILMANOCEPT TC 99M;
TRAMETINIB;
TRASTUZUMAB EMTANSINE;
UMECLIDINIUM PLUS VILANTEROL;
UNCLASSIFIED DRUG;
UNINDEXED DRUG;
VEMURAFENIB;
VORTIOXETINE;
COBICISTAT;
ELVITEGRAVIR;
SUVOREXANT;
DRUG APPROVAL;
DRUG INDUSTRY;
DRUG RESEARCH;
FOOD AND DRUG ADMINISTRATION;
HUMAN;
PRIORITY JOURNAL;
REVIEW;
TREATMENT INDICATION;
VIRUS GENOME;
ARTICLE;
BREAST METASTASIS;
DRUG MARKETING;
DRUG PROGRAM;
DRUG RECALL;
DRUG SAFETY;
DRUG SCREENING;
DYSPAREUNIA;
FAMILIAL HYPERCHOLESTEROLEMIA;
FINANCIAL MANAGEMENT;
LICENCE;
MULTIPLE MYELOMA;
NON INSULIN DEPENDENT DIABETES MELLITUS;
SEIZURE;
DRUG APPROVAL;
DRUG DISCOVERY;
DRUGS, INVESTIGATIONAL;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
|
EID: 84893311803
PISSN: 14741776
EISSN: 14741784
Source Type: Journal
DOI: 10.1038/nrd4239 Document Type: Review |
|
Times cited : (96)
|
|
References (0)
|
